Why it matters: Converge Medical Technology LLC is expanding its Washington presence just months after entering federal lobbying. The medical tech firm’s decision to add Maven Advocacy Partners LLC signals growing urgency around FDA regulations and federal funding opportunities in their sector.
By the numbers: Converge first registered to lobby in August 2025. The company is now working with Maven’s Jeffrey Joseph Burton, who brings over 10 years of lobbying experience. Burton has handled $5.7 million in total lobbying expenditures across all clients since 2013. His healthcare experience includes $930,000 for Blue Cross Blue Shield Association and $185,000 for Health Care Service Corp.
Broader context: The FDA issued new AI guidance for medical devices in April 2023. Clinical laboratory regulations under CLIA are changing, with new rules taking effect December 28, 2024. The government launched Project NextGen, a $5 billion program for medical countermeasures. BARDA announced multiple new solicitations for medical technology development in late 2023.
The agenda: Converge is lobbying on three areas: medical research and clinical labs, science and technology, and health issues. The company hasn’t specified particular legislation in its filings. Their focus aligns with current congressional discussions on medical device regulation and healthcare technology standards.
Competitive landscape: No specific information was available about other companies lobbying on the same issues as Converge Medical Technology.
Between the lines: Burton’s congressional experience includes serving as Chief of Staff to Rep. Mike Conaway (R-TX) and Coalitions Director for the House Republican Steering Committee. His lobbying portfolio spans healthcare giants like Blue Cross Blue Shield and tech firms like Tesla. This combination positions Converge to navigate complex regulatory changes while pursuing federal contracts and funding.
The bottom line: Converge’s lobbying expansion reflects the medical technology sector’s regulatory complexity. With billions in new federal funding available and FDA rules rapidly evolving, the company is positioning itself to compete effectively in an increasingly regulated market.
Spot something wrong? Report an issue with this article